P. Gelot, H. Dutartre, and A. Khammari, Vemurafenib: an unusual UVA-induced photosensitivity, Exp Dermatol, vol.22, pp.297-298, 2013.

R. Gabeff, H. Dutartre, and A. Khammari, Phototoxicity of B-RAF inhibitors: exclusively due to UVA radiation and rapidly regressive, Eur J Dermatol, vol.25, pp.452-456, 2015.

J. D. Rinderknecht, S. M. Goldinger, and S. Rozati, RASopathic skin eruptions during vemurafenib therapy, PLoS One, vol.8, 2013.
DOI : 10.1371/journal.pone.0058721

URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0058721&type=printable

B. Dr-eno, A. Ribas, and J. Larkin, Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study, Ann Oncol, vol.28, pp.1137-1144, 2017.

M. Sanlorenzo, A. Choudhry, and I. Vujic, Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma, J Am Acad Dermatol, vol.71, pp.1102-1109, 2014.

G. Erfan, S. Puig, and C. Carrera, Development of cutaneous toxicities during selective anti-BRAF therapies: preventive role of combination with MEK inhibitors, Acta Derm Venereol, vol.97, p.12, 2017.